Cancer survivorship increasingly means navigating decades of post-treatment life, yet many gynecologic cancer survivors face an unexpected dilemma: managing debilitating menopausal symptoms while weighing cancer recurrence fears. This comprehensive safety analysis offers critical guidance for the growing population of women who survive endometrial, ovarian, and cervical cancers but struggle with treatment-induced menopause.
The evidence reveals that systemic hormone replacement therapy carries acceptable oncologic risk for most survivors, including those with low-risk early-stage endometrial cancer, most ovarian cancer subtypes, and cervical cancers regardless of cell type. Vulvar and vaginal cancer survivors also appear to face minimal additional risk. However, clear contraindications emerge for advanced or non-endometrioid endometrial cancers, uterine sarcomas, and specific ovarian cancer types like granulosa-cell tumors.
This risk stratification represents a significant evolution in survivorship care, challenging the blanket avoidance of hormones that has historically left many women suffering unnecessarily. The analysis also validates non-systemic alternatives including vaginal estrogens and selective estrogen receptor modulators for genitourinary symptoms, expanding the therapeutic toolkit. For the estimated 1.7 million gynecologic cancer survivors in the US alone, this evidence-based approach could substantially improve long-term quality of life while maintaining oncologic safety. The findings suggest that individualized risk assessment, rather than universal hormone avoidance, should guide survivorship care decisions.